Global Finance Media Group (GFM), born in California, is a multilingual, AI-driven, Web3-native technology finance media.

We combine AI content engine, Web3 trust protocol, blockchain asset foundation, RWA value bridge and stablecoin settlement system to rebuild the authenticity, transparency and verifiability of global information.

IRVINE, CA / ACCESS Newswire / December 24, 2025 / On the day researchers confirmed the longest known survival of a patient with a fully external total artificial heart, more than a decade, the only device of its kind ever approved by the Food and Drug Administration reported a stark reality: virtually no new implants in 2024.

Half a world away, Chinese state media and corporate presentations have told a far more triumphant story. With 13.7 million citizens suffering from heart failure and donor organs in chronic short supply, domestically developed artificial hearts have been hailed as a lifesaving national achievement.

A 20-week investigation by Global Financial Media, a California-based outlet launching today, has found that no true total artificial heart, one that replaces both ventricles and removes the native organ, has been approved for sale in China. The four leading companies, which have collectively raised more than $7 billion and carry individual valuations as high as $70 billion, have brought to market only left-ventricular assist devices (LVADs), a far less ambitious technology.

Public filings and promotional materials routinely describe these LVADs simply as "artificial hearts" and "permanent replacements." In one prospectus reviewed by GFM, the term "artificial heart" appeared 127 times; the phrase "left ventricular assist device" was largely absent from the main narrative.

Disclosed clinical data, where available, show right-heart failure risks as high as 53 percent and 30-day mortality after complications reaching 68 percent. With one partial exception, none of the companies have released survival outcomes for 50 or more patients followed for two years or longer.

The gap is not merely technological; it is institutional. When narrative outruns evidence and political achievement overshadows rigorous scrutiny, patients bear the cost.

The seven-part series, published today in eight languages, is available at https://www.gfm.news/

Contact:
Name: Jeff Morgan
Email: info@gfm.news

SOURCE: Global Financial Media Inc.